KOSDAQReal Estate & REITs035610

Solborn

₩4,915▲ 2.40%2026-11-18 close
Market Cap
₩134.4B
Turnover
₩74,011,715
Volume
20K
Shares out.
27.4M
PER
31.8×
PBR
0.6×
EPS
₩159
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

A Holding Company With Volatile Quarterly Earnings

Solborn is a holding company whose results depend heavily on its medical IT subsidiary. Operating profit rose in 2025, but profit attributable to controlling shareholders fell for a second straight year, and the third quarter of 2026 swung to an operating loss and a net loss attributable to controlling shareholders.

  1. 1

    Annual sales rose from KRW 93.8 billion in 2022 to KRW 120.7 billion in 2025, and operating profit turned to a profit in 2023 and stood at KRW 24.6 billion in 2025.

  2. 2

    Net income attributable to controlling shareholders peaked at KRW 38.2 billion in 2023, then declined in both 2024 and 2025 to KRW 20.9 billion.

  3. 3

    Net income attributable to controlling shareholders reached KRW 24.3 billion in the second quarter of 2026, the largest of the last five quarters, before a net loss attributable to controlling shareholders of KRW 16.4 billion in the third quarter.

  4. 4

    The debt ratio was 20.1% at the end of 2025, and the price-to-book ratio is below 1x, meaning the shares trade at a discount to book value.

  5. 5

    Net income attributable to controlling shareholders over the last four quarters totals only KRW 4.02 billion, so earnings-based metrics are highly sensitive to quarterly swings.

02

Business structure

Solborn is a holding company founded in 1994, and its main businesses are taking management stakes in other companies through share ownership and leasing real estate. As of 2026 it holds 14 affiliates, including a core medical IT company and a venture capital firm.

The center of the business is its core medical IT subsidiary, which handles medical imaging software and medical devices.

Growth in PACS (picture archiving and communication systems) sales and the provision of medical software were cited as drivers of consolidated sales growth in 2025, and growth in the subsidiary's medical device business was cited for the improvement in the first quarter of 2026.

PACS is a product category hospitals and other medical institutions adopt when building imaging workflows, so the subsidiary's sales performance flows directly into the holding company's consolidated results. Sales at the parent-only level are small relative to consolidated sales.

Aggregated data show R&D spending fell from about KRW 8.8 billion in 2022 (9.40% of sales) to about KRW 6.9 billion in 2025 (5.69% of sales). Competition among PACS suppliers centers on functionality, stability, and implementation services. In 2025 the company disclosed that its stake in the affiliate KineMaster had increased to 37.44%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩27B₩4.4B16.5%
2025Q4₩28.7B₩4.4B15.2%
2026Q1₩35.3B₩3.6B10.3%
2026Q2₩35B₩16B45.9%
2026Q3₩25.2B-₩4.6B−18.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩93.8B-₩26.8B-₩41.7B−28.6%−33.7%21.0%
2023₩123.4B₩31.8B₩38.2B25.7%23.2%19.4%
2024₩116.1B₩21.2B₩34B18.2%16.8%19.5%
2025₩120.7B₩24.6B₩20.9B20.4%9.8%20.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales rose from KRW 93.8 billion in 2022 to KRW 123.4 billion in 2023, a 31.5% increase, then fell 5.9% to KRW 116.1 billion in 2024 and recovered 3.9% to KRW 120.7 billion in 2025. Among 2022 to 2025, 2023 was the largest year for sales and 2022 was the smallest.

Operating profit moved from an operating loss of KRW 26.8 billion in 2022 to operating profit of KRW 31.8 billion in 2023, a swing to profit. It then fell 33.3% to KRW 21.2 billion in 2024 and rose 16.3% to KRW 24.6 billion in 2025.

The operating margin was 25.7% in 2023, 18.2% in 2024, and 20.4% in 2025, so it dipped in 2024 and partly recovered in 2025. Net income attributable to controlling shareholders peaked at KRW 38.2 billion in 2023, then fell 11.0% to KRW 34 billion in 2024 and 38.7% to KRW 20.9 billion in 2025.

Net income including non-controlling interests rose from KRW 48.9 billion in 2023 to KRW 54.3 billion in 2024, then fell to KRW 34.5 billion in 2025.

Of the 2025 figure, KRW 20.9 billion belongs to controlling shareholders, and the remainder reflects non-controlling interests, so the two measures should be read separately.

Quarterly sales were KRW 27 billion in the third quarter of 2025, KRW 28.7 billion in the fourth quarter (up 6.2% from the prior quarter), and KRW 35.3 billion in the first quarter of 2026 (up 23.2%).

They then edged down to KRW 35 billion in the second quarter (down 0.9%) and fell to KRW 25.2 billion in the third quarter (down 27.9%), marking two consecutive quarterly declines.

Operating profit jumped to KRW 16 billion in the second quarter of 2026, up 342.0% from the prior quarter, before the third quarter posted an operating loss of KRW 4.57 billion.

Net income attributable to controlling shareholders alternated between loss and profit, with a KRW 5.28 billion loss in the fourth quarter of 2025, a KRW 1.42 billion profit in the first quarter of 2026, a KRW 24.3 billion profit in the second quarter, and a KRW 16.4 billion loss in the third quarter.

Whether the second-quarter profit and third-quarter loss reflect one-off items or a recurring pattern cannot be judged from the disclosed figures alone, so the notes and income breakdown in the next annual report need to be checked.

Operating cash flow was relatively steady at KRW 14.8 billion in 2022, KRW 11.2 billion in 2023, and KRW 15.1 billion in both 2024 and 2025.

05

Industry analysis

Solborn is classified under real estate and REITs, but its business structure is closer to a holding company than to a REIT. Its core activities are holding stakes in other companies and leasing real estate.

When comparing it with listed REITs such as Macquarie Korea Infrastructure Fund, SK REIT, or Lotte REIT, the earnings structure differs at the outset.

A REIT distributes cash largely based on rental income and asset value, whereas Solborn's earnings depend on its affiliates, particularly the medical IT subsidiary's sales and profitability.

The medical imaging IT market is generally understood to be influenced by hospital equipment investment and replacement cycles, so the subsidiary's quarterly sales can vary widely with hospital spending.

Consolidated sales moved from KRW 35.3 billion in the first quarter of 2026 to KRW 25.2 billion in the third quarter, a sizable swing within a single year. The position of the medical segment within consolidated results is the most important variable for interpreting the holding company's earnings.

Real estate leasing is small at the parent level, so the forces driving consolidated results sit more on the subsidiary side. Market share and market growth figures against competitors are not included in the numbers used here, and valuation comparisons against industry averages are likewise not presented as figures.

On this basis, the company's position within its sector is closer to a diversified holding structure than to a rental-income REIT.

06

Outlook

The company's disclosed annual targets, order backlog, or capacity expansion schedules are not part of the basis for this report. Three factors currently shape the earnings outlook. The first is the continued sales growth of PACS products at the core medical IT subsidiary, which drove consolidated sales growth in 2025.

The second is the growth in the subsidiary's medical device business cited for the first quarter of 2026. The third is the company's disclosure that its stake in the affiliate KineMaster had risen to 37.44%, and how this change in ownership affects future earnings needs to be checked. Weak factors are also clear.

Sales declined for two straight quarters in the second and third quarters of 2026, and the third quarter showed both an operating loss and a net loss attributable to controlling shareholders.

Whether the second-quarter operating profit of KRW 16 billion and the net income of KRW 24.3 billion attributable to controlling shareholders recur, or were one-off, is the most important judgment point.

The next annual report for 2026 will confirm fourth-quarter results, the full-year operating margin, and net income attributable to controlling shareholders. The points to check there are whether the third-quarter loss carried into the fourth quarter and whether subsidiary sales recovered to the 2025 level.

The size of non-controlling interests relative to the controlling shareholders' profit also needs to be examined alongside this. The first-quarter 2027 quarterly report can use the first quarter of 2026, with sales of KRW 35.3 billion and operating profit of KRW 3.63 billion, as a comparison base. The outlook could change if the company discloses order backlog or capacity plans.

07

Valuation

PER
31.8×
PBR
0.6×
ROE
1.8%
EPS
₩159
BPS
₩8,481
Dividend per share
₩0

The price-to-book ratio is below 1x, meaning the share price is under the net asset value attributable to controlling shareholders. This represents a discount to book value, but whether the discount reflects the prospect of earnings recovery depends on how the subsidiary stakes are carried on the balance sheet.

The price-earnings ratio is hard to interpret because controlling-shareholder profit declined in 2024 and 2025 and the company swung to a loss in the third quarter of 2026.

Over the last four quarters, net income attributable to controlling shareholders totals only KRW 4.02 billion, so an earnings-based multiple can move sharply with a single quarter's result. The dividend payout level is currently low, so a dividend-based view of the share price is difficult to form.

Because controlling-shareholder equity makes up a large part of total equity, asset-based valuation depends heavily on how the value of subsidiary stakes is assessed. The debt ratio of 20.1% at the end of 2025 indicates a modest financial burden, which provides some stability in the valuation context.

This fact does not indicate the direction of the share price, and the assessment should be made together with the profit breakdown in the next annual report and the subsidiary's results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Operating Profit Has Held Up Since 2023

Operating profit turned to KRW 31.8 billion in 2023 and held at KRW 24.6 billion in 2025. The 2025 figure rose 16.3% from 2024, and the operating margin improved from 18.2% to 20.4% over the same period. At the operating level, the earnings structure has kept a certain level of stability, which is a bullish factor.

Low Debt Ratio and Steady Operating Cash Flow

The debt ratio was 20.1% at the end of 2025, and total liabilities were KRW 62.6 billion. Operating cash flow edged up from KRW 14.8 billion in 2022 to KRW 15.1 billion in 2025 and has been broadly stable apart from 2023. The modest financial burden could be read as capacity to fund subsidiary investment and stake increases.

Second-Quarter 2026 Profit Jump and Subsidiary Growth

Operating profit in the second quarter of 2026 was KRW 16 billion, and net income attributable to controlling shareholders was KRW 24.3 billion, the largest of the last five quarters. Growth in PACS sales and the medical device business at the core subsidiary was cited as the background to the improvement.

If this level of profit repeats on a quarterly basis, it would serve as evidence of a structural improvement in the holding company's earnings.

09

Bear factors

Two Straight Years of Declining Controlling-Shareholder Profit

Net income attributable to controlling shareholders fell from KRW 38.2 billion in 2023 to KRW 34 billion in 2024 and KRW 20.9 billion in 2025, a second straight annual decline. The 2025 drop was 38.7%.

Net income including non-controlling interests also fell from KRW 54.3 billion in 2024 to KRW 34.5 billion in 2025, which signals weakening consolidated earnings.

Operating Loss and Controlling-Shareholder Net Loss in Q3 2026

Third-quarter 2026 sales were KRW 25.2 billion, down 27.9% from the prior quarter, and the company posted an operating loss of KRW 4.57 billion and a net loss attributable to controlling shareholders of KRW 16.4 billion.

The third quarter of 2025 had net income attributable to controlling shareholders of KRW 14.8 billion, so the swing into a loss is clear. Net income attributable to controlling shareholders over the last four quarters totals only KRW 4.02 billion.

Dependence on Subsidiaries and Quarterly Volatility

Solborn is a holding company with affiliates, so much of its profit depends on subsidiary results. The swing from a profit surge in the second quarter of 2026 to a loss in the third quarter shows that quarterly volatility is large and earnings are hard to predict.

The dividend payout level is also low, so it is difficult to cushion earnings swings through shareholder returns.

10

Risk factors

Subsidiary Earnings Volatility

A large part of sales and profit depends on sales at the medical IT subsidiary, so changes in hospital equipment spending or order flow could significantly move the holding company's results.

Quarterly sales moved from KRW 35.3 billion in the first quarter of 2026 to KRW 25.2 billion in the third quarter, a sizable swing within one year. Whether this volatility narrows is the next point to check.

Non-Controlling Interests and Profit Interpretation

Of the KRW 34.5 billion net income in 2025, KRW 20.9 billion belongs to controlling shareholders, so the gap between consolidated profit and the shareholder share is large. Of total equity of KRW 311.9 billion, the controlling-shareholder portion is KRW 212.6 billion.

Assessing the profit that actually accrues to shareholders requires reading net income attributable to controlling shareholders and non-controlling interests separately.

Stake Increases in Affiliates and Investment Burden

Solborn disclosed that its stake in the affiliate KineMaster had increased to 37.44%. A higher stake could affect the reflected value of the holding and future profit recognition, but investment cost and exit timing are not set by the disclosure alone. It needs to be confirmed how this investment affects holding-company cash flow and financial capacity.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    The 2026 annual report will confirm fourth-quarter results, the full-year operating margin, and net income attributable to controlling shareholders. The key point is whether the third-quarter operating loss continued into the fourth quarter.

  2. Around May 15, 2027 (first-quarter 2027 quarterly report deadline)

    The first quarter of 2026, with sales of KRW 35.3 billion and operating profit of KRW 3.63 billion, serves as the comparison base. It will show whether subsidiary medical device sales recover on a quarterly basis.

  3. Around August 14, 2027 (second-quarter 2027 quarterly report deadline)

    Whether the KRW 24.3 billion of net income attributable to controlling shareholders in the second quarter of 2026 recurs, or depended on one-off items, should be checked in the footnotes.

12

Overall view

Solborn is a holding company with a core medical IT subsidiary. After turning to operating profit in 2023, operating profit held at around KRW 24.6 billion through 2025.

Net income attributable to controlling shareholders, however, peaked at KRW 38.2 billion in 2023 and declined in both 2024 and 2025 to KRW 20.9 billion.

In the second quarter of 2026, operating profit rose to KRW 16 billion and net income attributable to controlling shareholders to KRW 24.3 billion, but the third quarter swung to an operating loss and a net loss attributable to controlling shareholders.

The financial structure is not heavily burdened, with a debt ratio of 20.1% at the end of 2025, and operating cash flow of KRW 15.1 billion in 2025 has been stable. The price-to-book ratio is below 1x, a factual comparison showing the shares trade at a discount to book value.

On the other hand, net income attributable to controlling shareholders over the last four quarters totals only KRW 4.02 billion, so earnings-based metrics are sensitive to quarterly results.

The next checkpoint is the 2026 annual report, when fourth-quarter results and full-year profit are confirmed, and it will be important to check whether the third-quarter loss persisted and whether second-quarter profit was one-off.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. comp.fnguide.com
  3. comp.fnguide.com
  4. comp.wisereport.co.kr
  5. butler.works
  6. comp.fnguide.com
  7. thevc.kr
  8. m.thinkpool.com
  9. tradingkey.com
  10. datatooza.com
  11. kr.investing.com
  12. stocktitan.net
  13. manilatimes.net
  14. globenewswire.com
  15. gurufocus.com
  16. businesswire.com
  17. globenewswire.com
  18. kr.investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis